This novel mechanism provides a comprehensive understanding of both OSBPL3 and the RAS signaling pathway in the progression of CRC and indicates that the HIF1A–OSBPL3–RAS axis may be a potential target for early therapeutic intervention in CRC progression. Here, OSBPL3 is linked to colorectal carcinoma.